Kadcyla is now available for patients with advanced HER2-positive breast cancer. Kadcyla is the first medicine of its kind in breast cancer, consisting of the HER2-targeted antibody, trastuzumab (contained in the medicine Herceptin), linked with the chemotherapy agent, DM1.
More...